I half-wondered if Mr. Carter would receive the BMS (Opdivo
®) or Merck (Keytruda
®) breakthrough therapy, when I read of his interview, last evening, in the
Gray Lady. Now we know -- he will. And we may well see outstanding results, even for a patient in his 90s. It is indeed a heady time for science.
I'll have more later -- on a train, at the moment. . . This could be a nice institutional marketing coup -- for Kenilworth, if he sees any progression free survival, of statistical significance.
Okay -- do
go read it:
. . . [The former President] immediately began treatment with a drug that’s new to the market. Carter is receiving pembrolizumab, better known by its brand name, Keytruda, according to the Washington Post. . . .
Of course, since the use is experimental -- and prescribed directly by his oncologists -- presumably without any input from Merck, proper, there is no off-label regulatory concern, for Merck.
More soon... Onward -- and we wish Mr. Carter the very best here.
No comments:
Post a Comment